{"schema_version":"secwatch.filing_event.v1","accession":"0001093557-22-000170","form_type":"8-K","ticker":"DXCM","cik":"0001093557","company_name":"DEXCOM INC","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.585548+00:00","generated_at":"2026-06-22T23:30:33.060949+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Dexcom Q3 revenue $769.6M (+18% YoY); non-GAAP EPS $0.28; guides FY22 ~$2.88-2.91B","bullets":["Revenue $769.6M, up 18% reported, 20% organic; US +17%, international +22% reported (+28% organic).","GAAP net income $101.2M ($0.24 EPS); non-GAAP net income $111.9M ($0.28 EPS).","Non-GAAP operating margin 20.9% (up 190 bps YoY); GAAP operating income $147.5M.","Initiated international rollout of Dexcom G7 in UK, Ireland, Germany, Austria, Hong Kong.","FY22 revenue guidance updated to ~$2.88-2.91B (18-19% growth); non-GAAP operating margin ~16%."],"urls":{"canonical":"https://secwatch.observer/filing/0001093557-22-000170","json":"https://secwatch.observer/filing/0001093557-22-000170.json","markdown":"https://secwatch.observer/filing/0001093557-22-000170.md","text":"https://secwatch.observer/filing/0001093557-22-000170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1093557/000109355722000170/0001093557-22-000170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1093557/000109355722000170/dxcm-20221027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:30:33.060949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}